Congresses

Title Yearsort descending
Development Of An Efficient In Vitro High-Throughput Method To Discover New Combinatorial Therapies Against Non-Tuberculous Mycobacteria 2020
IMPLEMENTATION OF THE HOLLOW FIBER SYSTEM FOR ANTIMICROBIAL RESEARCH 2020
Resistance to selamectin in Mycobacterium smegmatis is associated with changes in the mycobacterial envelope 2020
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Clinical trial design optimisation and dose rationale for the treatment of Buruli ulcer antibiotic combination therapy 2021
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens 2022
Régimen con betalactámicos para reducir el tratamiento de la úlcera de Buruli: tratamiento estándar de 8 semanas (rifampicina más claritromicina) versus 4 semanas de tratamiento estándar más amoxicilina/clavulanato [RC8 vs. RCA4] (ensayo clínico BLMs4BU) 2022
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative 2022
OPTIKA, a new high content in vitro kill-kinetic assay to evaluate the efficacy of novel anti-TB drug combinations 2022
In vitro synergy screens of FDA-approved drugs combined with last-line antibiotics reveal new bactericidal combinations against Klebsiella pneumoniae 2022
Hollow fiber system for tuberculosis setting up at university of Zaragoza 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
In vitro killing dynamics of the diarylquinolone TBAJ-587 and its main metabolites against Mycobacterium tuberculosis 2022
Shortening Buruli ulcer treatment: WHO recommended <i>vs.</i> a novel betalactam containing therapy - Phase II and Phase III studies in West Africa (the BLMs4BU clinical trial) 2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022

Pages